echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > And reputation bio-FGFR4 inhibitor declaration clinical domestic and foreign no drug with the same target listed

    And reputation bio-FGFR4 inhibitor declaration clinical domestic and foreign no drug with the same target listed

    • Last Update: 2020-05-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    ABSK-011 is an innovative FGFR4 small molecule oral inhibitor independently developed by Yuya Pharma and with global intellectual property rightsFGFR belongs to the tyrosine receptor kinase family, which includes four receptor subtypes (FGFR1-4), whose receptor activation plays a vital role in the growth, proliferation, survival, and metastasis of multiple tumorsIt is found that there is often the phenomenon of overactivation of FGFR4 signaling pathways in liver cancer, so the mechanism can be achieved to inhibit tumor growth by inhibiting the active blocking-related signal conduction of FGFR4liver cancer in Asia (especially in China) is a high incidence of cancer, and the current treatment methods are limited, the effect is not ideal, there are serious clinical lying needsAt present, there is no domestic and foreign fGFR4 target drugs on the market.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.